Form 4: Aquestive Therapeutics CEO Daniel Barber Acquires Stock and Options
SEC Form 4 Filing
Daniel Barber, CEO of Aquestive Therapeutics, acquired common stock and stock options on March 7, 2024, as reported in a Form 4 filing with the SEC.
Summary
- On March 7, 2024, Daniel Barber, the President and CEO of Aquestive Therapeutics, acquired 242,600 shares of common stock and 363,900 non-qualified stock options.
- The common stock was acquired at a price of $0 and is represented by restricted stock vesting in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment.
- The stock options, with an exercise price of $5.68, also vest in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment, and expire on March 7, 2034.
- Following the reported transactions, Barber directly owns 883,302 shares of common stock and 363,900 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's acquisition of stock and options suggests confidence, but it's a routine transaction.
Positives
- The CEO's acquisition of stock and options could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CEO's recent acquisition of company stock and options, which is a common occurrence.
Stakeholder Impact
- The CEO's stock acquisition could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: acquisition of common stock and stock options. |
| 03/07/2034 | Expiration date of the non-qualified stock options. |
| 03/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.